HAE
HAEMONETICS CORPCompany Information
- Company Name
- HAEMONETICS CORP
- CIK
- CIK0000313143
- Category
- Large accelerated filer
- Ticker: Exchange
- HAE: NYSE
- Fiscal Year End
- April 03
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- HAE
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-10
- Last sale
- 2024-07-26
- Shares purchased (TTM)
- 1,400
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 48,124,967
- Shares outstanding
- 45,361,000
- Ownership
- 106.09%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 22.28%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 223 | 245 | 363 | 296 | 293 | 307 | 321 | 299 | 344 | 179 | 194 | 351 | ||||||
| Accounts Receivable Net Current | 216 | 217 | 196 | 207 | 201 | 203 | 212 | 214 | 201 | 207 | 212 | 174 | ||||||
| Inventory Net | 307 | 306 | 321 | 336 | 361 | 365 | 360 | 382 | 374 | 317 | 304 | 286 | ||||||
| Prepaid Expense And Other Assets Current | 65 | 66 | 63 | 60 | 59 | 60 | 113 | 61 | 59 | 66 | 55 | 55 | ||||||
| Assets Current | 811 | 835 | 944 | 900 | 913 | 935 | 1,006 | 956 | 979 | 769 | 765 | 866 | ||||||
| Property Plant And Equipment Net | 304 | 306 | 297 | 292 | 287 | 284 | 286 | 300 | 302 | 311 | 319 | 308 | ||||||
| Intangible Assets Net Excluding Goodwill | 435 | 448 | 420 | 428 | 451 | 456 | 466 | 488 | 495 | 406 | 429 | 251 | ||||||
| Goodwill | 657 | 656 | 607 | 606 | 607 | 604 | 605 | 616 | 613 | 565 | 555 | 465 | ||||||
| Deferred Income Tax Assets Net | 9 | 10 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 8 | 5 | 5 | ||||||
| Other Assets Noncurrent | 150 | 142 | 216 | 208 | 196 | 164 | 160 | 156 | 142 | 136 | 127 | 117 | ||||||
| Assets | 2,365 | 2,396 | 2,491 | 2,442 | 2,462 | 2,451 | 2,531 | 2,525 | 2,541 | 2,196 | 2,200 | 2,011 | ||||||
Liabilities Current | ||||||||||||||||||
| Long Term Debt Current | 5 | 5 | 305 | 304 | 304 | 304 | 5 | 5 | 5 | 10 | 14 | 14 | ||||||
| Accounts Payable Current | 56 | 51 | 49 | 62 | 46 | 67 | 63 | 69 | 77 | 73 | 57 | 80 | ||||||
| Employee Related Liabilities Current | 38 | 68 | 52 | 48 | 36 | 59 | 46 | 49 | 41 | 81 | 59 | 46 | ||||||
| Other Liabilities Current | 164 | 158 | 134 | 134 | 146 | 148 | 139 | 150 | 137 | 136 | 132 | 125 | ||||||
| Liabilities Current | 263 | 283 | 540 | 548 | 531 | 578 | 253 | 274 | 260 | 300 | 262 | 264 | ||||||
| Long Term Debt Noncurrent | 1,169 | 1,220 | 920 | 920 | 921 | 921 | 1,220 | 1,220 | 1,218 | 798 | 857 | 749 | ||||||
| Deferred Income Tax Liabilities Net | 39 | 38 | 56 | 58 | 59 | 63 | 61 | 63 | 65 | 63 | 62 | 35 | ||||||
| Other Liabilities Noncurrent | 57 | 59 | 64 | 66 | 68 | 68 | 90 | 90 | 92 | 75 | 76 | 70 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 567 | 554 | 565 | 553 | 562 | 523 | 570 | 544 | 561 | 635 | 627 | 617 | ||||||
| Retained Earnings Accumulated Deficit | 312 | 279 | 381 | 336 | 356 | 352 | 392 | 369 | 387 | 360 | 340 | 309 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -42 | -38 | -35 | -41 | -36 | -55 | -56 | -35 | -43 | -36 | -24 | -33 | ||||||
| Stockholders Equity | 837 | 796 | 911 | 849 | 882 | 821 | 907 | 879 | 905 | 960 | 943 | 894 | ||||||
| Liabilities And Stockholders Equity | 2,365 | 2,396 | 2,491 | 2,442 | 2,462 | 2,451 | 2,531 | 2,525 | 2,541 | 2,196 | 2,200 | 2,011 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 4 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | 375 | 364 | 352 | 340 | 331 | 316 | 312 | 485 | 470 | 455 | 443 | 433 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 45 | 45 | 47 | 47 | 48 | 48 | 50 | 50 | 51 | 51 | 51 | 51 | ||||||
| Shares Outstanding | 45 | 45 | 47 | 47 | 48 | 48 | 50 | 50 | 51 | 51 | 51 | 51 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHAEMONETICS CORP (HAE) — SEC Financial Statements & Analysis
HAEMONETICS CORP (HAE) is a surgical & medical instruments & apparatus company, incorporated in MA. HAEMONETICS CORP trades on NYSE as: HAE. HAEMONETICS CORP (HAE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, HAEMONETICS CORP carries a market cap of $3.40B, a P/E ratio of 35.33x, a P/B ratio of 4.06x, a P/S ratio of 3.38x, an enterprise value of $4.35B, and an EV/EBITDA multiple of 16.10x. On profitability, it posts a gross margin of 79.37%, an operating margin of 15.94%, a net margin of 9.57%, a Return on Equity (ROE) of 11.20%, a Return on Assets (ROA) of 3.99%, and a Return on Invested Capital (ROIC) of 6.50%. Per share, it reports EPS of $2.12, diluted EPS of $2.11, free cash flow per share of $6.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -0.96% year-over-year, net income growth of -41.05% year-over-year, and EPS growth of -37.48% year-over-year. On the balance sheet, it maintains a current ratio of 3.08x, a quick ratio of 1.67x, working capital of $547.60M, a debt-to-equity ratio of 0.31x, a debt ratio of 0.11, free cash flow of $291.22M (TTM), and net debt of $950.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.40B
- P/E TTM
- 35.33x
- EPS TTM
- $2.12
- P/B TTM
- 4.06x
- ROE TTM
- 11.20%
- ROA TTM
- 3.99%
- Debt To Equity
- 0.31x
- Free Cash Flow TTM
- $291.22M
- Net Revenue TTM Growth 1Y
- -0.96%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is HAEMONETICS CORP in?
HAEMONETICS CORP (HAE) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does HAE trade on?
HAEMONETICS CORP (HAE) trades on the NYSE.
Where is HAEMONETICS CORP incorporated?
HAEMONETICS CORP is incorporated in MA.
When was HAEMONETICS CORP (HAE)'s most recent SEC filing?
HAEMONETICS CORP (HAE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is HAE's market cap?
HAEMONETICS CORP (HAE) has a market capitalization of $3.40B as of 2026-06-30.
What is HAE's P/E ratio?
HAEMONETICS CORP (HAE)'s trailing twelve month P/E ratio is 35.33x as of 2026-06-30.
What is HAE's EPS (earnings per share)?
HAEMONETICS CORP (HAE)'s trailing twelve month EPS is $2.12 as of 2026-06-30.
What is HAE's ROE (return on equity)?
HAEMONETICS CORP (HAE)'s trailing twelve month Return on Equity (ROE) is 11.20% as of 2026-06-30.
What is HAE's ROA (return on assets)?
HAEMONETICS CORP (HAE)'s trailing twelve month Return on Assets (ROA) is 3.99% as of 2026-06-30.
What is HAE's ROIC (return on invested capital)?
HAEMONETICS CORP (HAE)'s trailing twelve month Return on Invested Capital (ROIC) is 6.50% as of 2026-06-30.
What is HAE's EV/EBITDA?
HAEMONETICS CORP (HAE)'s trailing twelve month EV/EBITDA is 16.10x as of 2026-06-30.